脊柱关节炎诊断及治疗进展..ppt

  1. 1、本文档共64页,可阅读全部内容。
  2. 2、原创力文档(book118)网站文档一经付费(服务费),不意味着购买了该文档的版权,仅供个人/单位学习、研究之用,不得用于商业用途,未经授权,严禁复制、发行、汇编、翻译或者网络传播等,侵权必究。
  3. 3、本站所有内容均由合作方或网友上传,本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺!文档内容仅供研究参考,付费前请自行鉴别。如您付费,意味着您自己接受本站规则且自行承担风险,本站不退款、不进行额外附加服务;查看《如何避免下载的几个坑》。如果您已付费下载过本站文档,您可以点击 这里二次下载
  4. 4、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等,请点击“版权申诉”(推荐),也可以打举报电话:400-050-0827(电话支持时间:9:00-18:30)。
查看更多
脊柱关节炎诊断及治疗进展.

新指南提升关节外表现的诊疗价值,并明确对单抗类和融合蛋白类TNFi做出区分 Ward MM et al. Presented at ACR 2014. 治疗方案的选择 早诊断、早治疗 联合治疗 个体化 随诊调整方案 谢谢大家 * * * * * * * * * AS的治疗是否有效,是否可以达标?需要定期监测疾病活动度指标,那么评估AS疾病活动度指标有哪些呢? BASDAI :即Bath强直性脊柱炎疾病活动指数:包括疲乏、中轴及外周关节疼痛、晨僵和肌腱端痛,共有6个问题组成,让患者回答过去1周的症状。前5个问题用10cm VAS法完成,最高得10分,最后1个问题根据晨僵时间长短而得分。 ≥4提示疾病活动。 C反应蛋白为炎性反应指标之一,正常值不超过10mg/L,升高表示炎性反应活跃。 另外,核磁也是评估活动性炎症损伤的指标。 2010年ASAS指南推荐AS缓解评估指标: 缓解标准:BASDAI 50%改善或绝对值改善2分(0-10分)及专家建议; 评估时间:至少12周。 参考文献 Désirée van der Heijde , et al. Ann Rheum Dis 2011;70:905–908 汪年松.强直性脊柱炎.人民卫生出版社.2009:89-90 I-H Song, et al. Ann Rheum Dis 2011;70:590–596 * * * * * Objective. To evaluate the efficacy and safety of celecoxib in patients with ankylosing spondylitis (AS). Methods. This was a 12-week randomized, double-blind, placebo-controlled study with 4 treatment arms: celecoxib 200 mg qd, celecoxib 400 mg qd, naproxen 500 mg bid, and placebo. Patients (age 18–75 yrs) requiring daily treatment with nonselective nonsteroidal antiinflammatory drugs, and with a pain intensity on visual analog scale (VAS) 3 50 mm worsening by 30% compared with a preinclusion visit (14 days prior) were studied. Primary endpoints were least-squares mean changes from baseline in pain intensity, disease activity (patient global assessment VAS), and functional impairment [Bath Ankylosing Spondylitis Functional Index (BASFI)]. Adverse events were monitored throughout the study. Results. Of 611 randomized patients, 137 were allocated to celecoxib 200 mg, 161 to celecoxib 400 mg, 157 to naproxen, and 156 to placebo. Improvements in least-squares mean pain intensity, disease activity, and BASFI scores were significantly greater in the celecoxib 200 mg, celecoxib 400 mg, and naproxen groups than in the placebo group (p 2 0.001) at Week 12 and the interim timepoints, Weeks 1, 3, and 6. Celecoxib 400 mg was as effective as naproxen; however, naproxen was more effective than celecoxib 200 mg. Celecoxib was well tolerated, with an adverse event profile similar to placebo.

您可能关注的文档

文档评论(0)

153****9595 + 关注
实名认证
内容提供者

该用户很懒,什么也没介绍

1亿VIP精品文档

相关文档